Dear COVID-19 Working and sub-group members,
The 2nd release is now available – https://doi.org/10.15497/rda00046
Newsletters and communication to the community are now being published. and
there are some highlights for you below.
My sincerest thanks you all for the tireless effort, resources and
expertise that you are all investing to generate these important and
required Recommendations and Guidelines.
Wishing you a pleasant weekend
Hilary
*2nd Release Highlights:*
During the week since the first release we have seen the addition of two
cross-cutting COVID-19 sub-groups focusing on Legal and Ethical aspects and
Software. The seven sub-groups have kept up their relentless pace and the
main updates in this version, with respect to the 1st release on the 24
April 2020, include:
· Section 3 -Foundational Principles/Recommendations – modifications
· Section 4 – Clinical – updated
· Section 6 – Epidemiology – revised
· Section 8 – Omics – revised
· Section 9 – Overarching Research Software Guidelines – new
sub-section 9.3 initial guidelines for policy makers included
· Section 10 – Overarching Legal and Ethical Guidelines added
Furthermore, the editorial team have incorporated some of the feedback
received via the Requests for Comments (RfC) process and sent directly to
Co-chairs, Sub-group moderators and the Editorial team.
The social sciences and community participation sub-groups are working on
updates and additions for future releases.
You are invited to visit each of the sub-group pages (accessible from the
COVID-19 Working Group landing page) to see specific ongoing activities and
links to documents and resources.
*Timing, Future Releases and weekly webinars:*
In terms of timing, we foresee weekly releases (every Friday) between now
and 22 May 2020. More information and insights on the plans for those
releases, as well as highlights from the sub-groups are given during the
weekly webinar every Tuesday at 11UTC – see Events
page for details and to
access previous recordings and presentations.
*Request for Comments:*
As always, your feedback on the content of the releases, the scope, the
direction, is vital for all involved to shape and focus the document and
the sections to be a useful and meaningful tool.
Providing comments is easy:
1. Log in to the RDA web site
2. Go to the Outputs page
3. Scroll to the bottom of the page
4. Write your comments in the box (you may upload notes/attachments
too if you wish)
5. Select “Save”
*Call for Expertise:*
*The Clinical Subgroup would greatly appreciate the help from clinical
imaging data and immunological data experts. Please join the COVID-19
Clinical group at *https://www.rd-alliance.org/groups/rda-covid19-clinical
or contact the RDA Secretariat at enquiries[at]rd-alliance.org
_____________________________________
Hilary Hanahoe
Secretary General Research Data Alliance
Tel: +39-345-4719284
email: ***@***.***-foundation.org
skype: hilary.hanahoe
Twitter: @hilaryhanahoe
Orcid ID: 0000-0002-0328-3419
Web: http://www.rd-alliance.org
RDA Foundation: https://www.rd-alliance.org/about-rda/rda-foundation
_____________________________________
RDA 16th Plenary Meeting, 10 – 12 November 2020, San Jose, Costa Rica – see
updates
RDA 17th Plenary Meeting, 20 -22 April 2021, Edinburgh, Scotland – see
updates
IDW2021 *(co-organised by RDA, CODATA and WDS and incorporates 18th RDA
Plenary Meeting)*, 8-11 November 2021, Seoul, Republic of Korea – see
updates
_____________________________________
The information contained in this message and any attachments are intended
solely for the attention and use of the named addressee and may be
confidential. If you are not the intended recipient, you are reminded that
the information remains the property of the sender. You must not use,
disclose, distribute, copy, print or rely on this e-mail. If you have
received this message in error, please contact the sender immediately and
irrevocably delete or destroy this message and any copies.

Homepage